On August 30, 2026, Ascletis said the first participant was dosed in AURORA, its global Phase 3 program of once-daily oral ASC30 for chronic weight management. ASC30 is an investigational small-molecule GLP-1 receptor agonist. It is not a peptide.
The program will compare three maintenance doses with placebo over 72 weeks in two randomized trials. Combined enrollment is estimated at about 4,600 people. The company expects topline data in the third quarter of 2028 and a U.S. New Drug Application by the end of 2028.
First-patient dosing starts the pivotal program. It does not show that ASC30 works, that it is safe at 72 weeks, or that FDA will approve it.
What happened
Ascletis announced the first AURORA dose on August 30, 2026, in a company release carried by PR Newswire. The release describes ASC30 as a proprietary once-daily oral small-molecule glucagon-like peptide-1 receptor agonist in development for chronic weight management and diabetes.
The Hong Kong listing disclosure came earlier. In an August 3, 2026 HKEX filing, Ascletis said FDA had cleared the Phase 3 program and that the company had initiated two pivotal trials: AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450). That filing set the public timeline still used on August 30: topline data in the third quarter of 2028, a U.S. NDA by the end of 2028, and a European Medicines Agency Marketing Authorisation Application in early 2029.
Both ClinicalTrials.gov records now list the studies as recruiting.
| Program item | Recorded detail | Source |
|---|---|---|
| AURORA-1 | NCT07743463, recruiting, estimated n=3,003, obesity or overweight without type 2 diabetes | ClinicalTrials.gov |
| AURORA-2 | NCT07743450, recruiting, estimated n=1,560, obesity or overweight with type 2 diabetes | ClinicalTrials.gov |
| Combined size | About 4,600 participants | August 30 company release; August 3 HKEX filing |
| Geography | Company materials: United States, Europe, and Canada. AURORA-1 currently lists 120 locations across 7 countries. AURORA-2 lists 136 locations across 6 countries. | Company release; ClinicalTrials.gov |
| Duration | 72 weeks | Company release; HKEX filing; registry primary endpoints |
| Topline and filing plan | Topline in Q3 2028; U.S. NDA by end of 2028; EMA MAA in early 2029 | Company release; HKEX filing |
3,003 plus 1,560 equals 4,563. That is the arithmetic behind the company's "approximately 4,600" figure.
Why a small-molecule oral GLP-1 matters here
PeptidePrices covers peptide research and the GLP-1 market around it. Semaglutide, tirzepatide, and retatrutide are peptides. The weekly injectables in that class are amino-acid chains.
ASC30 is a different chemical class. The company and the ADA 2026 abstract describe it as an oral small molecule with a similar chemical scaffold to orforglipron and differentiated pharmacological properties. Orforglipron is already the first approved oral small-molecule GLP-1. See our orforglipron explainer.
A small molecule can be formulated as a conventional tablet. It does not need the peptide-protection steps used by oral semaglutide. That is why oral small-molecule GLP-1 programs sit next to peptide injectables in pipeline coverage, including our ADA 2026 GLP-1 roundup.
The shared comparison is the receptor target. The molecule class is not. A Phase 3 start does not make ASC30 interchangeable with semaglutide, tirzepatide, or orforglipron.
What the Phase 3 trials will test
Both AURORA studies are Phase 3, randomized, double-blind, placebo-controlled, and parallel-group. ClinicalTrials.gov lists triple masking. Participants receive once-daily oral ASC30 tablets or matching placebo.
Company materials specify three maintenance doses: 20 mg, 40 mg, and 60 mg. The public registry records describe three experimental cohorts plus placebo. They do not print those milligram amounts on the pages fetched for this article. The dose numbers below come from the August 30 company release and the August 3 HKEX filing.
| Design item | AURORA-1 (NCT07743463) | AURORA-2 (NCT07743450) |
|---|---|---|
| Status | Recruiting | Recruiting |
| Estimated enrollment | 3,003 | 1,560 |
| Population | Adults 18 and older with obesity or overweight, without type 2 diabetes | Adults 18 and older with obesity or overweight and type 2 diabetes |
| BMI entry | At least 30 kg/m2, or at least 27 kg/m2 plus a listed comorbidity | At least 27 kg/m2 |
| Other entry rules | At least one unsuccessful dietary weight-loss effort. Comorbidities listed: hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. | Type 2 diabetes diagnosis and HbA1c greater than 6.5% through 10.5%. At least one unsuccessful dietary weight-loss effort. |
| Key exclusions | Prior diabetes except gestational diabetes; recent weight change over 5 kg; pancreatitis history; personal or family history of medullary thyroid carcinoma or MEN2 | Type 1 diabetes or other non-T2D diabetes; recent weight change over 5 kg; pancreatitis history; personal or family history of medullary thyroid carcinoma or MEN2 |
| Intervention | Once-daily oral ASC30, three experimental cohorts | Once-daily oral ASC30, three experimental cohorts |
| Comparator | Matching daily placebo | Matching daily placebo |
| Primary endpoint | Percent change in body weight from baseline to week 72 | Percent change in body weight from baseline to week 72 |
| Notable secondaries | Waist, blood pressure, lipids, BMI, HbA1c, fasting glucose, fasting insulin | HbA1c, fasting glucose, blood pressure, lipids, BMI, fasting insulin, waist |
| Registered dates | Start August 2026; primary completion and completion July 2028 | Start August 2026; primary completion and completion July 2028 |
AURORA-1 is the obesity-without-diabetes trial. AURORA-2 is the type 2 diabetes trial. The primary question in both is the same: percent weight change at week 72 versus placebo. Glycemic change is secondary in AURORA-2, not the primary endpoint.
The HKEX filing adds titration length: 12 weeks for the 20 mg cohort, 16 weeks for 40 mg, and 20 weeks for 60 mg. Those titration windows sit inside the 72-week treatment period. They are protocol details from the company filing, not independent efficacy results.
July 2028 completion dates on ClinicalTrials.gov line up with a third-quarter 2028 topline. Both dates remain estimates.
Phase 2 evidence and its limits
The completed U.S. Phase 2 record is NCT07002905. It was a Phase IIa, randomized, double-blind, placebo-controlled study. Actual enrollment was 125. The primary endpoint was percent change in body weight from baseline to week 13. The study started July 3, 2025, and completed December 8, 2025, at six U.S. sites. Participants were 18 to 75 years old. Prior diabetes was an exclusion.
The weight-change numbers now attached to that study come from a sponsor-authored ADA abstract, not from a completed 72-week pivotal paper.
1672-P, published June 5, 2026, in Diabetes (DOI 10.2337/db26-1672-p), reports a 13-week, randomized, double-blind, placebo-controlled, multicenter U.S. Phase 2 study. A total of 125 participants were randomized to placebo or oral ASC30 with target doses of 20 mg, 40 mg, or 60 mg once daily via weekly titration.
At week 13, the abstract reports placebo-adjusted weight reductions of 5.4%, 7.0%, and 7.7% for the 20 mg, 40 mg, and 60 mg groups. Mean baseline body weight was 107.3 kg. Mean baseline BMI was 38.6 kg/m2. The abstract says the curve showed no plateau at week 13.
On safety, the abstract says all gastrointestinal adverse events were grade 1 or 2 and occurred mainly during titration. It reports no grade 3 or higher drug-related adverse events or serious adverse events. Discontinuation because of adverse events was 7.3% in the 20 mg group, 7.5% in the 40 mg group, 0.0% in the 60 mg group, and 0.0% with placebo. The listed authors are Jinzi J. Wu and Vanessa Wang.
| Phase 2 item | Reported figure | Limit |
|---|---|---|
| Sample | 125 randomized | Small dose-finding cohort, not a pivotal sample |
| Duration | 13 weeks | AURORA's primary look is week 72 |
| 20 mg | 5.4% placebo-adjusted weight reduction | Placebo-adjusted, not an unadjusted 72-week result |
| 40 mg | 7.0% placebo-adjusted weight reduction | Same 13-week window |
| 60 mg | 7.7% placebo-adjusted weight reduction | Highest 13-week figure in this abstract |
| Baseline | 107.3 kg; BMI 38.6 kg/m2 | Obesity-without-diabetes population |
| AE discontinuations | 7.3%, 7.5%, 0.0% vs 0.0% placebo | Short follow-up; 0% at 60 mg is a small-cell observation |
| Grade 3 or higher drug-related AEs or SAEs | None reported | Does not establish 72-week safety |
The 7.7% figure is placebo-adjusted at 13 weeks in 125 people. It is not a 72-week pivotal result.
The abstract also compares vomiting and overall gastrointestinal tolerability with orforglipron titration schedules. That comparison is not a head-to-head trial. Cross-trial tolerability percentages are not proof that ASC30 is easier to stay on than orforglipron.
The abstract's "best-in-class" conclusion is the authors' framing. It is not a regulatory finding.
What this does not mean
- First patient dosed is not FDA approval. It is an operational milestone. ASC30 remains investigational.
- Phase 3 enrollment does not prove efficacy or safety. Randomization and recruitment are the start of the test, not the result.
- The 7.7% figure is not a 72-week label claim. It is a placebo-adjusted week-13 result from 125 people in a sponsor-backed ADA abstract.
- No-plateau language is a 13-week observation. It does not show that weight loss continues, or that it is durable, through 72 weeks.
- Cross-trial GI comparisons are not head-to-head proof. The abstract's orforglipron tolerability remarks compare separate programs and titration schedules.
- ASC30 is not a peptide. Research-vendor "GLP-1 peptide" listings are not this investigational tablet.
- ASC30 is not available for prescribing or legitimate retail sale. A first dose in a trial is not market access.
- "Second oral small-molecule GLP-1 after orforglipron" is an if-approved company claim. The August 30 release and the August 3 HKEX filing both condition that ranking on later approval.
- Hepatic-safety language in the August 30 release is a company statement. It is not an independent 72-week safety review.
- The HKEX filing includes a listing caution. Ascletis says it cannot guarantee that it will develop, manufacture, or commercialize ASC30.
This article does not include a consumer dosing protocol. The milligram figures above are trial-design and abstract numbers.
What to watch next
The dated items to track are already on the public record.
- Recruitment versus the estimated sample. AURORA-1 is listed at 3,003 and AURORA-2 at 1,560. Both are estimates.
- Whether week 72 remains the primary weight look. That is the registered primary endpoint in both trials today.
- AURORA-2 glycemic secondaries. HbA1c is secondary there. Weight is still primary.
- The third-quarter 2028 topline. That is the company's stated readout window.
- The end-2028 U.S. NDA plan. A planned filing is not a submitted application and not an approval.
- A fuller Phase 2 paper, if one appears. The current efficacy table is an ADA abstract plus a completed registry record.
For the wider oral-versus-injectable map, see the ADA 2026 pipeline roundup and the site's GLP-1 indications beyond weight loss. Live semaglutide listing comparisons remain a price-and-vendor view of peptide products. They are not a source for ASC30.
FAQs
Did Ascletis start Phase 3 for ASC30?
Yes. The company said the first AURORA participant was dosed on August 30, 2026. ClinicalTrials.gov lists AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450) as recruiting.
Is ASC30 a peptide?
No. ASC30 is an investigational once-daily oral small-molecule GLP-1 receptor agonist. Semaglutide, tirzepatide, and retatrutide are peptides. Sharing a receptor class is not the same as sharing a chemical class.
What did Phase 2 show?
The completed U.S. Phase 2 study (NCT07002905) randomized 125 people for 13 weeks. The ADA abstract reports placebo-adjusted weight reductions of 5.4%, 7.0%, and 7.7% at 20 mg, 40 mg, and 60 mg. That is a short, sponsor-backed dataset, not a 72-week pivotal result.
Does first-patient dosing mean ASC30 works?
No. It means the Phase 3 program has begun dosing. Efficacy and longer-term safety are what AURORA is designed to measure.
When are results expected?
Ascletis says it expects topline AURORA data in the third quarter of 2028, a U.S. NDA by the end of 2028, and an EMA MAA in early 2029. ClinicalTrials.gov lists July 2028 as the estimated completion for both trials.
Can someone buy or be prescribed ASC30 now?
No. ASC30 is investigational. It is not FDA-approved and is not available for prescribing or legitimate retail sale.
This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions. ASC30 is an investigational small-molecule drug studied in controlled trials. Nothing here is a dosing protocol, an availability claim, or a recommendation to obtain an unapproved product.
Continue your research
- The First GLP-1 Pill Is Here: What Orforglipron (Foundayo) Actually Is
- What the GLP-1 Pipeline Showed at ADA 2026
- GLP-1s Are Becoming "Everything" Drugs
- Semaglutide price comparison
- Semaglutide research page
Sources
- ClinicalTrials.gov NCT07743463. AURORA-1: once-daily oral ASC30 in adults with obesity or overweight without type 2 diabetes
- ClinicalTrials.gov NCT07743450. AURORA-2: once-daily oral ASC30 in adults with obesity or overweight and type 2 diabetes
- ClinicalTrials.gov NCT07002905. Completed 13-week U.S. Phase IIa study of ASC30 tablets, actual enrollment 125
- Wu JJ, Wang V. 1672-P: Oral small molecule GLP-1, ASC30, demonstrated placebo-adjusted weight loss of 7.7% with better gastrointestinal tolerability in its 13-week U.S. Phase II study in participants with obesity. Diabetes. 2026;75(Supplement_1):1672-P. DOI 10.2337/db26-1672-p
- Ascletis. First participant dosed in a global Phase III clinical program of once-daily oral small molecule GLP-1 receptor agonist ASC30 for chronic weight management. PR Newswire. August 30, 2026
- Ascletis Pharma Inc. Voluntary announcement: initiation of global Phase III for oral small molecule GLP-1, ASC30. HKEX filing. August 3, 2026